184 related articles for article (PubMed ID: 22246440)
1. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo.
Menezes DL; Taverna P; Jensen MR; Abrams T; Stuart D; Yu GK; Duhl D; Machajewski T; Sellers WR; Pryer NK; Gao Z
Mol Cancer Ther; 2012 Mar; 11(3):730-9. PubMed ID: 22246440
[TBL] [Abstract][Full Text] [Related]
2. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
3. Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.
Fu J; Koul D; Yao J; Wang S; Yuan Y; Colman H; Sulman EP; Lang FF; Yung WK
Cancer Res; 2013 May; 73(10):3062-74. PubMed ID: 23492364
[TBL] [Abstract][Full Text] [Related]
4. The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases.
Lamottke B; Kaiser M; Mieth M; Heider U; Gao Z; Nikolova Z; Jensen MR; Sterz J; von Metzler I; Sezer O
Eur J Haematol; 2012 May; 88(5):406-15. PubMed ID: 22309072
[TBL] [Abstract][Full Text] [Related]
5. Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800.
Massey AJ; Schoepfer J; Brough PA; Brueggen J; Chène P; Drysdale MJ; Pfaar U; Radimerski T; Ruetz S; Schweitzer A; Wood M; Garcia-Echeverria C; Jensen MR
Mol Cancer Ther; 2010 Apr; 9(4):906-19. PubMed ID: 20371713
[TBL] [Abstract][Full Text] [Related]
6. Design, structure-activity relationship, and in vivo characterization of the development candidate NVP-HSP990.
McBride CM; Levine B; Xia Y; Bellamacina C; Machajewski T; Gao Z; Renhowe P; Antonios-McCrea W; Barsanti P; Brinner K; Costales A; Doughan B; Lin X; Louie A; McKenna M; Mendenhall K; Poon D; Rico A; Wang M; Williams TE; Abrams T; Fong S; Hendrickson T; Lei D; Lin J; Menezes D; Pryer N; Taverna P; Xu Y; Zhou Y; Shafer CM
J Med Chem; 2014 Nov; 57(21):9124-9. PubMed ID: 25368984
[TBL] [Abstract][Full Text] [Related]
7. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
[TBL] [Abstract][Full Text] [Related]
8. Increased radiosensitivity and radiothermosensitivity of human pancreatic MIA PaCa-2 and U251 glioblastoma cell lines treated with the novel Hsp90 inhibitor NVP-HSP990.
Milanović D; Firat E; Grosu AL; Niedermann G
Radiat Oncol; 2013 Feb; 8():42. PubMed ID: 23448094
[TBL] [Abstract][Full Text] [Related]
9. Preclinical activity of the novel orally bioavailable HSP90 inhibitor NVP-HSP990 against multiple myeloma cells.
Stühmer T; Iskandarov K; Gao Z; Bumm T; Grella E; Jensen MR; Einsele H; Chatterjee M; Bargou RC
Anticancer Res; 2012 Feb; 32(2):453-62. PubMed ID: 22287732
[TBL] [Abstract][Full Text] [Related]
10. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
11. Hsp90 inhibitor HSP990 in very low dose upregulates EAAT2 and exerts potent antiepileptic activity.
Sha L; Chen T; Deng Y; Du T; Ma K; Zhu W; Shen Y; Xu Q
Theranostics; 2020; 10(18):8415-8429. PubMed ID: 32724478
[No Abstract] [Full Text] [Related]
12. Antiproliferative effect of HSP90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways.
Xue N; Jin J; Liu D; Yan R; Zhang S; Yu X; Chen X
Curr Cancer Drug Targets; 2014; 14(7):671-83. PubMed ID: 25219422
[TBL] [Abstract][Full Text] [Related]
13. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
[TBL] [Abstract][Full Text] [Related]
14. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.
Khong T; Spencer A
Mol Cancer Ther; 2011 Oct; 10(10):1909-17. PubMed ID: 21859842
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Evaluation of the Tumor Cell Growth Inhibitory Potential of New Putative HSP90 Inhibitors.
Bizarro A; Sousa D; Lima RT; Musso L; Cincinelli R; Zuco V; De Cesare M; Dallavalle S; Vasconcelos MH
Molecules; 2018 Feb; 23(2):. PubMed ID: 29438315
[TBL] [Abstract][Full Text] [Related]
16. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.
Spreafico A; Delord JP; De Mattos-Arruda L; Berge Y; Rodon J; Cottura E; Bedard PL; Akimov M; Lu H; Pain S; Kaag A; Siu LL; Cortes J
Br J Cancer; 2015 Feb; 112(4):650-9. PubMed ID: 25625276
[TBL] [Abstract][Full Text] [Related]
17. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
[TBL] [Abstract][Full Text] [Related]
18. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ
Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma.
Okui T; Shimo T; Hassan NM; Fukazawa T; Kurio N; Takaoka M; Naomoto Y; Sasaki A
Anticancer Res; 2011 Apr; 31(4):1197-204. PubMed ID: 21508365
[TBL] [Abstract][Full Text] [Related]
20. Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells.
Zitzmann K; Ailer G; Vlotides G; Spoettl G; Maurer J; Göke B; Beuschlein F; Auernhammer CJ
Int J Oncol; 2013 Dec; 43(6):1824-32. PubMed ID: 24100469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]